Pages that link to "Q33113039"
Jump to navigation
Jump to search
The following pages link to Marc Humbert (Q33113039):
Displaying 50 items.
- Benfluorex and unexplained valvular heart disease: a case-control study (Q21091138) (← links)
- Scaling up strategies of the chronic respiratory disease programme of the European Innovation Partnership on Active and Healthy Ageing (Action Plan B3: Area 5) (Q26740215) (← links)
- Riociguat: Mode of action and clinical development in pulmonary hypertension (Q26748684) (← links)
- The molecular targets of approved treatments for pulmonary arterial hypertension (Q26798308) (← links)
- Pulmonary manifestations of antisynthetase syndrome (Q26800639) (← links)
- The role of combination therapy in managing pulmonary arterial hypertension (Q26823839) (← links)
- A critical analysis of survival in pulmonary arterial hypertension (Q26827578) (← links)
- Genetics and genomics of pulmonary arterial hypertension (Q27004610) (← links)
- New perspectives in long-term outcomes in clinical trials of pulmonary arterial hypertension (Q27024711) (← links)
- Implementing the ESC/ERS pulmonary hypertension guidelines: real-life cases from a national referral centre (Q27693923) (← links)
- Risk assessment in pulmonary arterial hypertension (Q28067184) (← links)
- Management of pulmonary arterial hypertension (Q28081181) (← links)
- Advances in therapeutic interventions for patients with pulmonary arterial hypertension (Q28085443) (← links)
- Intrinsic asthma (Q28196639) (← links)
- Function of the serotonin 5-hydroxytryptamine 2B receptor in pulmonary hypertension (Q28203160) (← links)
- Stress Doppler echocardiography in relatives of patients with idiopathic and familial pulmonary arterial hypertension: results of a multicenter European analysis of pulmonary artery pressure response to exercise and hypoxia (Q28239012) (← links)
- Nuclear IL-33 regulates soluble ST2 receptor and IL-6 expression in primary human arterial endothelial cells and is decreased in idiopathic pulmonary arterial hypertension (Q28243527) (← links)
- ARIA 2016: Care pathways implementing emerging technologies for predictive medicine in rhinitis and asthma across the life cycle (Q28355722) (← links)
- Temporal asthma patterns using repeated questionnaires over 13 years in a large French cohort of women (Q28533462) (← links)
- Diagnosis and Classification of 17 Diseases from 1404 Subjects via Pattern Analysis of Exhaled Molecules (Q28818128) (← links)
- Pulmonary arterial hypertension in idiopathic inflammatory myopathies: Data from the French pulmonary hypertension registry and review of the literature (Q30245016) (← links)
- Seasonality in asthma: Impact and treatments (Q30251666) (← links)
- Recommendations for screening and detection of connective tissue disease-associated pulmonary arterial hypertension (Q30562538) (← links)
- Current epoprostenol use in patients with severe idiopathic, heritable or anorexigen-associated pulmonary arterial hypertension: data from the French pulmonary hypertension registry (Q30757591) (← links)
- Palliative Potts shunt for the treatment of children with drug-refractory pulmonary arterial hypertension: updated data from the first 24 patients. (Q30874440) (← links)
- BMPR2 mutations and survival in pulmonary arterial hypertension: an individual participant data meta-analysis (Q31038854) (← links)
- Short-term and long-term epoprostenol (prostacyclin) therapy in pulmonary hypertension secondary to connective tissue diseases: results of a pilot study. (Q33144907) (← links)
- Use of Amplatzer fenestrated atrial septal defect device in a child with familial pulmonary hypertension (Q33154476) (← links)
- Riociguat for the treatment of pulmonary arterial hypertension (Q33163083) (← links)
- [Treatment of pulmonary arterial hypertension]. (Q33164660) (← links)
- Platelet-derived growth factor expression and function in idiopathic pulmonary arterial hypertension (Q33329056) (← links)
- Treatment of pulmonary hypertension secondary to connective tissue diseases. (Q33634193) (← links)
- Pulmonary hypertension related to drugs and toxins. (Q33740484) (← links)
- N-acetylcysteine improves established monocrotaline-induced pulmonary hypertension in rats (Q33786092) (← links)
- Key role of the endothelial TGF-β/ALK1/endoglin signaling pathway in humans and rodents pulmonary hypertension (Q33793407) (← links)
- Inflammation and immunity in the pathogenesis of pulmonary arterial hypertension (Q33898213) (← links)
- Systemic sclerosis-associated pulmonary arterial hypertension (Q33950086) (← links)
- Absence of influence of gender and BMPR2 mutation type on clinical phenotypes of pulmonary arterial hypertension. (Q33968765) (← links)
- Pulmonary arterial hypertension in France: results from a national registry (Q33993302) (← links)
- Clinical and molecular genetic features of pulmonary hypertension in patients with hereditary hemorrhagic telangiectasia. (Q34085780) (← links)
- Risk factors for pulmonary arterial hypertension. (Q34094102) (← links)
- Pulmonary hypertension complicating sarcoidosis. (Q34276008) (← links)
- Systematic analysis of blood cell transcriptome in end-stage chronic respiratory diseases (Q34373840) (← links)
- Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension. (Q34424315) (← links)
- 2014 ESC guidelines on the diagnosis and management of acute pulmonary embolism (Q34436061) (← links)
- 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): (Q34491530) (← links)
- Comparative Safety and Tolerability of Prostacyclins in Pulmonary Hypertension (Q34508259) (← links)
- Strategic plan for lung vascular research: An NHLBI-ORDR Workshop Report (Q34535086) (← links)
- World Health Organization; GA(2)LEN; AllerGen. Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen) (Q34589248) (← links)
- Fenfluramine-like cardiovascular side-effects of benfluorex. (Q34658157) (← links)